Vaccines 2024, 12(10), 1148; https://doi.org/10.3390/vaccines12101148 - 8 Oct 2024
Best Paper Award
The Vaccines Best Paper Award is granted annually to highlight publications of high quality, scientific significance, and extensive influence. Evaluation committee members will choose four articles of exceptional quality published in the journal two years prior and announce the winners online by the end of June.
The Prize:
– Two review awards: CHF 400 and the opportunity to publish a paper free of charge in Vaccines in 2025 following peer review;
– Two research article awards: CHF 500 and the opportunity to publish a paper free of charge in Vaccines in 2025 following peer review;
– Each winner will also receive a certificate.
Vaccines Best Paper Award
Eligibility and Requirements
– All papers published in Vaccines in 2023 are eligible (both regular and Special Issue submissions).
Selection Criteria
– Scientific merit and broad impact;
– Originality of the research objectives and/or the ideas presented;
– Creativity of the study design or uniqueness of the approaches and concepts;
– Clarity of presentation;
– Citations and downloads.
Past Winners
Year:
Winner
Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery
Transforming Aquaculture through Vaccination: A Review on Recent Developments and Milestones
Vaccines 2024, 12(7), 732; https://doi.org/10.3390/vaccines12070732 - 1 Jul 2024
Development of NP-Based Universal Vaccine for Influenza A Viruses
Vaccines 2024, 12(2), 157; https://doi.org/10.3390/vaccines12020157 - 2 Feb 2024
Award Committee
Prof. Ger Rijkers
Chairperson
University College Roosevelt
Prof. Jorge Leitão
Instituto Superior Técnico, Universidade de Lisboa
Dr. James Galloway
Prof. Dr. Seth Pincus
Montana State University
Winner
An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
Vaccines 2023, 11(1), 130; https://doi.org/10.3390/vaccines11010130 - 5 Jan 2023
Factors Influencing Antibody Response to SARS-CoV-2 Vaccination
Vaccines 2023, 11(2), 451; https://doi.org/10.3390/vaccines11020451 - 15 Feb 2023
The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives
Vaccines 2023, 11(2), 333; https://doi.org/10.3390/vaccines11020333 - 1 Feb 2023
Award Committee
Dr. Ralph Tripp
Chairperson
Univ Georgia
Prof. Christian Napoli
Department of Medical surgical sciences and translational medicine - Sapienza University of Rome
Dr. Zixin Wang
JC School of Public Health and Primary Care, the Chinese University of Hong Kong
Prof. Michael Bukrinsky
The George Washington University
Dr. Mariusz Skwarczynski
University of Queensland
Winner
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Vaccines 2022, 10(5), 819; https://doi.org/10.3390/vaccines10050819 - 22 May 2022
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
Vaccines 2022, 10(2), 227; https://doi.org/10.3390/vaccines10020227 - 2 Feb 2022
Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women
Vaccines 2022, 10(1), 101; https://doi.org/10.3390/vaccines10010101 - 10 Jan 2022
Award Committee
Dr. Ralph Tripp
Chairperson
Univ Georgia
Prof. Michael Bukrinsky
The George Washington University
Prof. Christian Napoli
Department of Medical surgical sciences and translational medicine - Sapienza University of Rome
Prof. Sara Louise Cosby
Queen's University Belfast
Dr. Yashdeep Phanse
University of Wisconsin-Madison
Winner
Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic
Vaccines 2021, 9(3), 210; https://doi.org/10.3390/vaccines9030210 - 3 Mar 2021
Willingness to Receive COVID-19 Vaccination in Japan
Vaccines 2021, 9(1), 48; https://doi.org/10.3390/vaccines9010048 - 14 Jan 2021
Nanomaterial Delivery Systems for mRNA Vaccines
Vaccines 2021, 9(1), 65; https://doi.org/10.3390/vaccines9010065 - 19 Jan 2021
Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines
Vaccines 2021, 9(4), 359; https://doi.org/10.3390/vaccines9040359 - 8 Apr 2021
